In breast cancer cells, treatment with Palbociclib, a CDK4/6 inhibitor, upregulates mechanistic target of rapamycin (mTOR) whilst promoting G0/G1 cell cycle arrest (Cretella et al., 2018). Here, MTOR is linked to breast cancer.